Tagged with Regulatory

AstraZeneca Rodrigo Fernandez became country president of AstraZeneca Central America, Caribbean, and Middle Andean Countries (CAMCARMAC) in July 2013. He discusses the challenges across the region for regulation and distribution channels, with an emphasis on the complexities of the Peruvian market. What were your initial priorities when you became head of…

regulatory Alejandro Luna and José Alfredo Sedano, lawyers at the leading legal firm of Santamarina y Steta, discuss the current legal challenges faced by companies in the pharmaceutical and healthcare sector in Mexico and urge for the amendment of the current regulatory framework. How was the healthcare and life science practice…

regulatory Santiago Garcia Belmonte, president of Biosidus, discusses how global regulatory trends are driving change in the Argentinian biotech industry, as well the new direction his firm has taken over the last five years. How would you describe the recent changes in the biotech market and the industries new direction? Things…

regulatory Eduardo Loyola has been at the helm of Heel’s Chilean affiliate for almost a decade. Prior to his appointment at Heel, Loyola was part of a working group that is responsible for the current regulatory framework for natural products. Loyola elaborates on the innovative marketing strategies Heel has undertaken to…

regulatory PharmaBoardroom first interviewed Erik Lommerde as general manager of Novo Nordisk Netherlands four years ago. In his new role as general manager of Novo Nordisk Spain & Portugal, he discusses the urgent need for government to trust in and collaborate with the subsidiary in preventative measures for diabetes, as well…

Almirall Having only arrived on the market last year, the GM of Almirall in Canada explains the company’s regulatory struggles, the utilization of Almirall’s global R&D infrastructure in Canada as well as the company’s choice to enter the Canadian market and what products they are introducing into it.   You started…